Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Aldastotug · PYX-106

Monoclonal antibody · Inhibitor of Siglec-15 · developed by Pyxis Oncology

Phase 1 Most advanced trial
PYXS Developer
1 Registered trials

What is Aldastotug?

Aldastotug is a humanized monoclonal antibody that binds Siglec-15, a cell surface protein overexpressed on tumor-associated macrophages and certain tumor cells. It acts as an immune checkpoint inhibitor, intended to disrupt macrophage-mediated suppression of CD8 and CD4 T-cell responses. It is studied in solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PYX-106
Drug type
Monoclonal antibody
Targets
Siglec-15
Mechanism
Inhibitor of Siglec-15
Pathways
T-cell response inhibition, tumor-associated macrophage survival and differentiation
Therapy area
Oncology
Developer
Pyxis Oncology, Inc (PYXS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
P63Y458LB9

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05718557 Phase 1 Solid Tumor Active not recruiting PYXS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumor

Other drugs acting on SIGLEC15

More from Pyxis Oncology

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PYXS page.

Follow PYXS, the company behind Aldastotug

See PYXS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PYXS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.